$0.961700
00.00%
Pre-Market: 4:02 PM EDT
Comments
Loading...
Prelude Therapeutics (NASDAQ:PRLD) Stock, Earnings Estimates, EPS, And Revenue
Prelude Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 13
EPS Estimate
$-0.490
Quarterly Revenue Estimate
–
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$3M
Analyze the earnings history of Prelude Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Prelude Therapeutics (PRLD) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-06 | $-0.43 | $-0.47 | 8.51 % |
| Jun 2024 | 2024-08-12 | $-0.46 | $-0.42 | -9.52 % |
| Mar 2024 | 2024-05-07 | $-0.42 | $-0.48 | 12.5 % |
| Dec 2023 | 2024-02-15 | $-0.45 | $-0.49 | 8.16 % |
Prelude Therapeutics (PRLD) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Prelude Therapeutics (NASDAQ:PRLD) reporting earnings?
Prelude Therapeutics (PRLD) is scheduled to report earnings on February 13, 2025. The last reported earnings were for reported on November 6, 2024 for Q3.
What were the latest earnings per share (EPS) for Prelude Therapeutics (NASDAQ:PRLD)?
The Actual EPS was $-0.43, which beat the estimate of $-0.47.
What were Prelude Therapeutics’s (NASDAQ:PRLD) revenues?
The Actual Revenue was $3M, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.